Sign inCreate account

Report workspace tools

NCT05254925COMPLETEDanonymous

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

Sponsor

Source record

dsm-firmenich Switzerland AG

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

6% Bemotrizinol (BEMT)

Indication / condition

AI-normalized

Phototoxic Response

Intervention

Source record

Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle

Source & freshness

Source record

NCT ID

NCT05254925

Original source

ClinicalTrials.gov

Source last updated

Aug 26, 2022

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05254925

Title

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

Sponsor

dsm-firmenich Switzerland AG

Status

COMPLETED

Phase

PHASE2

Condition raw

Phototoxic Response

Condition normalized

Phototoxic Response

Modality raw

Phototoxic Response

Modality normalized

small molecule

Target raw

6% Bemotrizinol (BEMT)

Target normalized

6% Bemotrizinol (BEMT)

Interventions

Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle

Public preview

Source record

This clinical trial evaluated the phototoxic potential of 6% Bemotrizinol in various formulations compared to vehicle controls. Conducted by dsm-firmenich Switzerland AG, the study aimed to assess safety and efficacy in human subjects, focusing on skin reactions post-UV exposure.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of Topically Applied Bemotrizinol for Human Phototoxic Potential

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05254925

Status

COMPLETED

Phase

PHASE2

Sponsor

dsm-firmenich Switzerland AG

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the phototoxic potential of 6% Bemotrizinol in various formulations compared to vehicle controls. Conducted by dsm-firmenich Switzerland AG, the study aimed to assess safety and efficacy in human subjects, focusing on skin reactions post-UV exposure.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedAug 26, 2022
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05254925

Indication

Phototoxic Response

Modality

small molecule

Target

6% Bemotrizinol (BEMT)

Intervention

Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.